ELI LILLY & Co (LLY)
About ELI LILLY & Co
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $65.2B
- Net income
- $20.6B
- Total assets
- $112.5B
- Market cap
- $1.0T
- Gross margin
- 83.0%
- Operating margin
- 39.5%
- Net margin
- 31.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $65.2B
- Cost of revenue
- $11.1B
- Gross profit
- $54.1B
- Operating expenses
- $28.4B
- Operating income
- $25.7B
- Income tax
- $5.1B
- Net income
- $20.6B
- EPS (basic)
- $23.00
- EPS (diluted)
- $22.95
Balance sheet
- Total assets
- $112.5B
- Current assets
- $55.6B
- Total liabilities
- $85.9B
- Current liabilities
- $35.2B
- Shareholders’ equity
- $26.5B
Cash flow
- Operating cash flow
- $16.8B
- Investing cash flow
- -$11.0B
- Financing cash flow
- -$2.2B
- Net cash flow
- $4.0B
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.0T
- P/E ratio
- 52.1
- EPS (diluted)
- $22.95
- Dividend yield
- 0.58%
- Shares outstanding
- 843.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 9, 1970
ELI LILLY & Co (LLY) Stock Price
- Profitable — net income of $20.6B in FY2025.
- Revenue grew 130% from FY2021 to FY2025.
- Gross margin of 83.0%, net margin 31.7%.
- Trading near its 52-week high.
- Pays a dividend yielding about 0.58% annually.
- Valued at a price-to-earnings (P/E) ratio of 52.1.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ELI LILLY & Co.
Write a review
News about ELI LILLY & Co
News & sentiment via Polygon.io
ELI LILLY & Co: frequently asked questions
Is ELI LILLY & Co an American company?
Yes — ELI LILLY & Co is an American company headquartered in Indianapolis, Indiana. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is ELI LILLY & Co headquartered?
ELI LILLY & Co is headquartered in Indianapolis, Indiana, United States.
Is ELI LILLY & Co publicly traded?
Yes — ELI LILLY & Co is a publicly traded company. Its stock trades under the ticker symbol LLY on the NYSE.
What does ELI LILLY & Co do?
ELI LILLY & Co is an American Pharmaceuticals company in the Health & Beauty sector.
When was ELI LILLY & Co founded?
ELI LILLY & Co was founded in 1875.
